<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Propofol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Propofol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Propofol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9826" href="/d/html/9826.html" rel="external">see "Propofol: Drug information"</a> and <a class="drug drug_patient" data-topicid="12103" href="/d/html/12103.html" rel="external">see "Propofol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F214584"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diprivan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868058"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Diprivan;</li>
<li>Propofol-II [DSC];</li>
<li>TEVA-Propofol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055140"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">General Anesthetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462565"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety</b>
<b>:</b> Consult local regulations and individual institutional policies and procedures; should only be used by experienced personnel who are not actively engaged in the procedure.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d270175f-972e-498c-9b7e-00dded2859a1">Endotracheal intubation, nonemergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation, nonemergent (outside operating room): </b>
<b>Note:</b> Use of an alternative agent is suggested. A prospective, multicenter, dose-finding study in neonates (n=91, median GA 27.7 weeks [IQR 25.9 to 30.6 weeks], median PNA 29 hours [IQR 3 to 213 hours]) was terminated early when an interim analysis showed that effective sedation could not be achieved without the occurrence of hypotension in the majority of neonates (59%), despite pretreatment with an IV fluid bolus; GA and PNA were shown not to be predictive of successful sedation or the occurrence of hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31932363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31932363'])">Ref</a></span>). Subsequent analysis of the study population showed a significant initial dose-dependent and prolonged decrease in blood pressure in neonates treated with standard propofol doses; duration of hypotension exceeded 60 minutes in all treatment groups studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32248549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32248549'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F214606"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Consult local regulations and individual institutional policies and procedures; should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage must be individualized based on total body weight and titrated to the desired clinical effect; the following are general dosing guidelines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee45596a-e3fc-4e6f-9910-a77ecacbb999">Anesthesia, general</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, general</b>
<b>:</b>
<b>Note:</b> Individualize dosing based on patient factors and concomitant anesthetic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction of general anesthesia:</i> Children ≥3 years and Adolescents &lt;17 years: IV: 2.5 to 3.5 mg/kg over 20 to 30 seconds. <b>Note:</b> Use a lower dose for ASA-PS III or IV.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance of general anesthesia:</i> Infants ≥2 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV bolus: Initial: IV: 1 to 4 mg/kg once; may administer additional smaller bolus doses if clinical signs of light anesthesia present; usual bolus dose: 0.5 to 2 mg/kg/dose; repeat as needed based on clinical response and desired level of anesthesia.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Initial dose immediately following induction: 200 to 300 mcg/kg/minute (12 to 18 mg/kg/<b>hour</b>); then decrease dose after 30 minutes if clinical signs of light anesthesia are absent; usual infusion rate after initial 30 minutes: 125 to 150 mcg/kg/minute (7.5 to 9 mg/kg/<b>hour</b>). <b>Note:</b> Younger pediatric patients may need higher infusion rates than older pediatric patients.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a9164b2-17e8-4f94-9ddb-f8a935bb05f3">ICU sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>ICU sedation (critically ill): </b>Limited data available: <b>Note: </b>Prior to use, consult local/state regulations and institutional policies and procedures regarding administration and monitoring requirements; dosing practices may vary.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 0.5 to 1 mg/kg once; maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Usual range: 16 to 66 mcg/kg/minute (1 to 4 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35119438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35119438'])">Ref</a></span>). <b>Note: </b>Monitor closely for signs and symptoms of propofol-related infusion syndrome (PRIS).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Repeated IV bolus method:</i> IV: Initial dose: 1 to 2 mg/kg; higher initial doses of 2 mg/kg are recommended in infants and children &lt;3 years of age; follow initial dose with 0.5 to 1 mg/kg every 3 to 5 minutes as needed until adequate level of sedation achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24438649','lexi-content-ref-21958025','lexi-content-ref-16517277','lexi-content-ref-30732981','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24438649','lexi-content-ref-21958025','lexi-content-ref-16517277','lexi-content-ref-30732981','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IV bolus followed by continuous IV infusion:</i> IV: Initial bolus: 1 to 2 mg/kg followed by continuous IV infusion: Dose range: 50 to 250 mcg/kg/minute (3 to 15 mg/kg/<b>hour</b>); titrate to desired level of sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cravero.1','lexi-content-ref-30732981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cravero.1','lexi-content-ref-30732981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Propofol with concurrent ketamine; emergency department procedures:</i> IV: 0.5 to 0.75 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24438649','lexi-content-ref-Cravero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24438649','lexi-content-ref-Cravero.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df5b5619-96a2-41fe-98f7-2be9d4ee6da5">Status epilepticus; refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus; refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial propofol infusion:</i> IV: Loading dose 1 to 2 mg/kg once, then initiate continuous IV infusion at 20 mcg/kg/minute (1.2 mg/kg/<b>hour</b>); titrate to desired effect (eg, burst suppression on EEG); usual dose range: 30 to 200 mcg/kg/minute (1.8 to 12 mg/kg/<b>hour</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>). <b>Note:</b> Use caution when administering high doses (&gt;65 mcg/kg/minute [&gt;3.9 mg/kg/<b>hour</b>]) for extended periods of time (&gt;48 hours); monitor closely for adverse effects (eg, propofol-related infusion syndrome [PRIS]); Neurocritical Care Society guidelines for status epilepticus state that use of propofol in young children is contraindicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Breakthrough seizure while on propofol infusion:</i> IV: Increase continuous IV infusion rate by 5 to 10 mcg/kg/minute (0.3 to 0.6 mg/kg/<b>hour</b>) every 5 minutes with or without an additional 1 mg/kg IV bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159508"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations in the manufacturer's labeling. In adults, no dosage adjustments are recommended.</p></div>
<div class="block dohp drugH1Div" id="F51159509"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations in the manufacturer's labeling. In adults, no dosage adjustments are recommended.</p></div>
<div class="block doa drugH1Div" id="F214588"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9826" href="/d/html/9826.html" rel="external">see "Propofol: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<b>Safety: </b>Consult local/state regulations and institutional policies and procedures regarding administration and monitoring requirements prior to use; dosing practices may vary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d181a5f4-ff4e-4c53-9710-1ef232f62b7c">General anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Individualize dosing based on patient factors and concomitant anesthetic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction of anesthesia:</b>
<b>Note:</b> In high-risk patients (eg, debilitated, American Society of Anesthesiologists - Physical Status [ASA-PS] 3 or 4, hemodynamically compromised), avoid rapid bolus administration to minimize hypotension. Induction doses may be administered in divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Healthy adults, ASA-PS 1 or 2:</i>
<b>IV:</b> Usual total dose: 1 to 2.5 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hemodynamic compromise or hypovolemia:</i>
<b>IV:</b> Usual total dose: 0.5 to 1.5 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Debilitated or ASA-PS 3 or 4:</i>
<b>IV:</b> Usual total dose: 0.5 to 1.5 mg/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance of anesthesia: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Healthy adults, ASA-PS 1 or 2:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous IV infusion:</b> Usual dosing range: 50 to 200 mcg/kg/minute; titrate to clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Debilitated or ASA-PS 3 or 4:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous IV infusion:</b> Usual dosing range: 50 to 100 mcg/kg/minute; titrate to clinical response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16f9dccd-d560-4631-83e4-036a7dc3f121">Rapid sequence intubation outside the operating room</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation outside the operating room (induction): Note:</b> May cause dose-related hypotension; consider alternative agent in patients who are hemodynamically unstable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37196592']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37196592'])">Ref</a></span>). Refer to local/state regulations and institutional policies and procedures regarding administration and monitoring requirements.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1.5 to 2 mg/kg once; usual dose range: 1 to 3 mg/kg. <b>Note:</b> Continuous infusion may be started if longer sedation is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caro.1','lexi-content-ref-Roberts.1','lexi-content-ref-24259635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caro.1','lexi-content-ref-Roberts.1','lexi-content-ref-24259635'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5b0cb2b-97d8-4c58-b27d-3b3dfbcb0a46">Sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mechanically ventilated patients in the ICU, sedation:</b>
<b>Note:</b> Used as part of a multimodal strategy (eg, combination of sedatives and analgesics) for ICU sedation and preferred over a benzodiazepine due to less risk of prolonged sedation and improved time to extubation; titrate to maintain a light level of sedation (eg, Richmond Agitation Sedation Scale 0 to −2) or clinical effect (eg, ventilator synchrony) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous IV infusion:</b> Initial: 5 mcg/kg/minute; increase by 5 to 10 mcg/kg/minute every 5 to 10 minutes until goal sedation level is achieved. Usual maintenance dose: 5 to 50 mcg/kg/minute. Maximum dose (not well defined; may vary by institution): 60 to 80 mcg/kg/minute. Daily awakening trials or use of nurse-protocolized sedation are recommended; generally, titrate down slowly to avoid rapid awakening. If agitated after discontinuation of continuous infusion, then restart at ~50% of the previous maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22436955','lexi-content-ref-10816184','lexi-content-ref-19874582','lexi-content-ref-23269131','lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22436955','lexi-content-ref-10816184','lexi-content-ref-19874582','lexi-content-ref-23269131','lexi-content-ref-30113379'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Monitored anesthesia care: Note:</b> Individualize dosing based on patient factors and concomitant anesthetic agents.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Healthy adults, ASA-PS 1 or 2:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous IV infusion:</b> Initial: 25 to 75 <b>mcg</b>/kg/minute; titrate to adequate sedation. <b>Note: </b>If rapid effect is desired, may initiate with a higher infusion rate (eg, 100 to 150 <b>mcg</b>/kg/minute for 3 to 5 minutes) or administer an initial bolus (eg, 0.25 to 0.5 <b>mg</b>/kg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosero.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosero.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>
<b>or</b></i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Intermittent bolus: 10 to 20 mg; may give additional doses as needed to achieve adequate sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosero.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosero.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Debilitated or ASA-PS 3 or 4:</i> Use reduced dose. Bolus slowly and avoid rapid repeat dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Procedural sedation, outside the operating room (off-label use): Note:</b> Monitor respiratory and cardiovascular systems; refer to local/state regulations and institutional policies and procedures regarding administration and monitoring requirements.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 0.5 to 1 mg/kg, followed by 0.25 to 0.5 mg/kg every 1 to 3 minutes, as needed, to achieve adequate sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30732981','lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30732981','lexi-content-ref-Roberts.1'])">Ref</a></span>). Alternatively, may consider an initial dose of 0.375 to 0.75 mg/kg when combined with ketamine (as a 1:1 mixture); repeat with ~0.188 to 0.375 mg/kg as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24438649','lexi-content-ref-22401952','lexi-content-ref-27460905','lexi-content-ref-36042988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24438649','lexi-content-ref-22401952','lexi-content-ref-27460905','lexi-content-ref-36042988'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3cf4716-2d40-4dd4-9822-7d4ea864180d">Status epilepticus, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus, refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used as an alternative or adjunctive agent to midazolam, barbiturates, or ketamine after conventional intermittent therapies have failed. Mechanical ventilation and hemodynamic support required; continuous EEG is recommended. Titrate doses to cessation of electrographic seizures or burst suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905'])">Ref</a></span>). Optimal regimen and dose are uncertain; refer to institutional protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Loading dose: 1 to 2 mg/kg, followed by 0.5 to 2 mg/kg every 3 to 5 minutes until seizures are suppressed; maximum total dose: 10 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> After initial loading dose, begin continuous infusion at an initial rate of 20 <b>mcg</b>/kg/minute; titrate to cessation of electrographic seizures or burst suppression. Usual dose range: 30 to 60 <b>mcg</b>/kg/minute. Maximum dose (not well defined and may vary by institution): 200 <b>mcg</b>/kg/minute. Use caution with doses &gt;80 <b>mcg</b>/kg/minute for &gt;48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">For breakthrough status epilepticus, administer bolus of 0.5 to 2 <b>mg</b>/kg every 3 to 5 minutes in addition to increasing continuous infusion rate by 5 to 10 <b>mcg</b>/kg/minute every 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274','lexi-content-ref-29922905'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Generally, a period of at least 24 hours of electrographic suppression is suggested prior to down titrating the continuous infusion; withdraw gradually by decreasing the dose 15% to 20% every 3 hours while continuing conventional therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-27544138','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-27544138','lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990705"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large V<sub>d</sub>, highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub>, highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Case reports of filter clotting in patients with propofol-associated hypertriglyceridemia receiving CRRT have been reported; monitor triglycerides and visually inspect the CRRT system for evidence of congealing or a “milky brown” appearance of the “clot” as a potential cause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24529993','lexi-content-ref-30158750','lexi-content-ref-32950175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24529993','lexi-content-ref-30158750','lexi-content-ref-32950175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Similar concerns for a potential for filter clotting exist in patients receiving PIRRT who experience propofol-associated hypertriglyceridemia; monitor triglycerides and visually inspect the PIRRT system for evidence of congealing or a “milky brown” appearance of the “clot” as a potential cause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988044"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F56076154"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac conduction disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Propofol may cause bradyarrhythmias (<b>bradycardia</b>) and convert tachyarrhythmias (<b>tachycardia</b>) to sinus rhythm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21642950','lexi-content-ref-20659617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21642950','lexi-content-ref-20659617'])">Ref</a></span>). May also be associated rarely with <b>prolonged QT interval on ECG</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18713888','lexi-content-ref-18717665','lexi-content-ref-2605073','lexi-content-ref-2343728','lexi-content-ref-8322572','lexi-content-ref-12131130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18713888','lexi-content-ref-18717665','lexi-content-ref-2605073','lexi-content-ref-2343728','lexi-content-ref-8322572','lexi-content-ref-12131130'])">Ref</a></span>) and <b>ECG abnormality</b> (shortening of the QT interval) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19225403','lexi-content-ref-12463387']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19225403','lexi-content-ref-12463387'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not clearly established; may be direct or indirect (more emerging data). Indirect effect may be related to modulation of autonomic nervous system tone through changes in the baroreceptor reflex, resulting in bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7639382','lexi-content-ref-1443685','lexi-content-ref-15721728','lexi-content-ref-20659617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7639382','lexi-content-ref-1443685','lexi-content-ref-15721728','lexi-content-ref-20659617'])">Ref</a></span>). QT prolongation is most likely relegated to dose and predisposed cardiac conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18973642','lexi-content-ref-19514884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18973642','lexi-content-ref-19514884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; both bradycardia and QT prolongation have been reported to occur rapidly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9215013','lexi-content-ref-Vuillaume.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9215013','lexi-content-ref-Vuillaume.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Bradycardia (possible risk factors):</p>
<p style="text-indent:-2em;margin-left:8em;">• High doses, prolonged duration of therapy (in association with propofol-related infusion syndrome [PRIS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent medications, such as beta-blockers, neostigmine, neuromuscular blockers, opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9215013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9215013'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous cardiac history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9215013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9215013'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Surgical issues, such as extradural anesthesia, previous syncope, preoperative conduction abnormalities, too light anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9215013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9215013'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">QT prolongation:</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-specific:</p>
<p style="text-indent:-2em;margin-left:10em;">- High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21642950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21642950'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Pediatric patients (in association with PRIS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vuillaume.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vuillaume.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• General:</p>
<p style="text-indent:-2em;margin-left:10em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- History of drug-induced torsades de pointes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Loop diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:10em;">- Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Propofol may rarely cause <b>anaphylaxis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21233125','lexi-content-ref-1642359','lexi-content-ref-10794344','lexi-content-ref-22174476','lexi-content-ref-1379418','lexi-content-ref-11878723','lexi-content-ref-18361011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21233125','lexi-content-ref-1642359','lexi-content-ref-10794344','lexi-content-ref-22174476','lexi-content-ref-1379418','lexi-content-ref-11878723','lexi-content-ref-18361011'])">Ref</a></span>), <b>angioedema</b>, and <b>bronchoconstriction</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11524333','lexi-content-ref-22211170']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11524333','lexi-content-ref-22211170'])">Ref</a></span>). Current evidence suggests that immediate hypersensitivity reactions associated with propofol are rare compared to other medications often administered at the same time (eg, antibiotics, neuromuscular blocking agents).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; immunologic or nonimmunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) can be IgE-mediated or non–IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22787384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22787384'])">Ref</a></span>). Propofol allergy may be due to the presence of the diisopropyl side chain or phenol group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1642359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1642359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Immediate hypersensitivity reactions: rapid; occur shortly after administration (often within 5 to 10 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21233125','lexi-content-ref-1642359','lexi-content-ref-22174476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21233125','lexi-content-ref-1642359','lexi-content-ref-22174476'])">Ref</a></span>); reported to occur after first exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1379418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1379418'])">Ref</a></span>) or after multiple exposures to propofol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1642359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1642359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Food allergy: Although propofol is mixed in a formulation containing soybean oil and egg lecithin, true allergy has been associated with soy and egg proteins and not these oils. Current evidence suggests that immediate hypersensitivity reactions associated with propofol are not predicted by a history of food allergy, including those with soy, egg, and peanut allergy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33529424','lexi-content-ref-31077340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33529424','lexi-content-ref-31077340'])">Ref</a></span>). Available studies have indicated that propofol may be used safely in soy- or egg-allergic patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26675952','lexi-content-ref-33529424','lexi-content-ref-21467558','lexi-content-ref-26089466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26675952','lexi-content-ref-33529424','lexi-content-ref-21467558','lexi-content-ref-26089466'])">Ref</a></span>). A statement issued by the American Academy of Allergy, Asthma and Immunology has concluded that patients with soy or egg allergy can receive propofol without any special precautions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAAAI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAAAI.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypertriglyceridemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia</b> can occur with propofol, which may lead to acute<b> pancreatitis. </b>Rare cases of propofol-induced acute pancreatitis have occurred in the absence of hypertriglyceridemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31283535','lexi-content-ref-10208230','lexi-content-ref-22797405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31283535','lexi-content-ref-10208230','lexi-content-ref-22797405'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-and duration-related; propofol is formulated as a ~10% lipid emulsion, which can cause hypertriglyceridemia and lead to acute pancreatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31283535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31283535'])">Ref</a></span>). Cases of propofol-induced acute pancreatitis that occur in the absence of hypertriglyceridemia have been described as idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22797405']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22797405'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; hypertriglyceridemia may occur at any time during therapy, but the median time ranges from 2 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33274340','lexi-content-ref-16185179','lexi-content-ref-33985368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33274340','lexi-content-ref-16185179','lexi-content-ref-33985368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Hypertriglyceridemia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Dose and duration: &gt;50 mcg/kg/minute for &gt;2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33274340','lexi-content-ref-16185179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33274340','lexi-content-ref-16185179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher severity of illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33274340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33274340'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer ICU stay (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33274340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33274340'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• SARS-CoV-2 positive (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33985368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33985368'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33274340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33274340'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute pancreatitis:</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting diseases or factors that predispose to acute pancreatitis (eg, alcohol use disorder, abdominal or cardiothoracic surgeries, hypertriglyceridemia, diabetes, family history of lipoproteinemia, obesity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31283535','lexi-content-ref-16185179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31283535','lexi-content-ref-16185179'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Propofol may cause severe <b>hypotension</b> (to the effect of ≥30% decrease in mean arterial pressure [MAP]), especially with bolus dosing or in the setting of hypovolemia, sepsis, or shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33528922','lexi-content-ref-22436955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33528922','lexi-content-ref-22436955'])">Ref</a></span>). May also induce hypotension in pediatric patients (neonates) and trauma patients (adults and pediatrics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31849243','lexi-content-ref-32067810','lexi-content-ref-20642659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31849243','lexi-content-ref-32067810','lexi-content-ref-20642659'])">Ref</a></span>). Propofol in neonatal endotracheal intubations may potentiate hypotension, leading to serious complications, such as intraventricular hemorrhage or periventricular leukomalacia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23889264','lexi-content-ref-20642659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23889264','lexi-content-ref-20642659'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism<i>:</i></i> Not clearly established; proposed mechanisms include reduction of peripheral resistance through a direct action in vascular smooth muscle (possibly from histamine release), inhibition of sympathetic activity on the vasculature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9009941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9009941'])">Ref</a></span>), and reduction in stressed volume caused by decreased venous and arterial resistance with no change in cardiac output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27199311']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27199311'])">Ref</a></span>). Propofol acts as a calcium channel blocker and beta-adrenergic antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9066334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9066334'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; propofol may induce hypotension after bolus administration, new continuous infusion initiation, or increases in the dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bolus dosing</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia</p>
<p style="text-indent:-2em;margin-left:6em;">• Older, debilitated, or American Society of Anesthesiologists - Physical Status (ASA-P) 3 or 4 patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline MAP 60 to 70 mm Hg prior to propofol administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24233892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24233892'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Changes to propofol infusion rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24233892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24233892'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Need for renal replacement therapy during treatment with propofol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24233892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24233892'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid sequence intubation in patients (adults and pediatrics) with trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30268185','lexi-content-ref-32067810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30268185','lexi-content-ref-32067810'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sepsis (adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31849243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31849243'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe aortic stenosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390417'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Trauma patients (adults): Age &gt;55 years, lower baseline systolic blood pressure, obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24399312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24399312'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preterm infants 29 to 32 gestational weeks with infant respiratory distress syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20642659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20642659'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Propofol-related infusion syndrome (PRIS)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Propofol-related infusion syndrome (PRIS), is a serious adverse reaction that has been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26290263','lexi-content-ref-30101390','lexi-content-ref-26558513','lexi-content-ref-19874582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26290263','lexi-content-ref-30101390','lexi-content-ref-26558513','lexi-content-ref-19874582'])">Ref</a></span>). PRIS is rare but has a high mortality rate and is characterized by a constellation of symptoms, including dysrhythmia (<b>bradycardia</b> or <b>tachycardia</b>), widening of the QRS complex, heart failure,<b> hypotension</b>, <b>asystole</b>, lipemia and <b>hypertriglyceridemia</b>, <b>metabolic acidosis</b>, and/or <b>rhabdomyolysis</b> or myoglobinuria with acute kidney injury and hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30101390','lexi-content-ref-21464061','lexi-content-ref-18664783','lexi-content-ref-30857601','lexi-content-ref-26558513','lexi-content-ref-19874582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30101390','lexi-content-ref-21464061','lexi-content-ref-18664783','lexi-content-ref-30857601','lexi-content-ref-26558513','lexi-content-ref-19874582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; may be due to a mitochondrial defect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24491974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24491974'])">Ref</a></span>). It is thought that propofol inhibits transportation of long-chain fatty acids into the cell and interferes with/uncouples oxidative phosphorylation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; between 1 to 4 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18225970','lexi-content-ref-23269131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18225970','lexi-content-ref-23269131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and duration: Usually ≥4 mg/kg/hour for ≥2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061','lexi-content-ref-30857601','lexi-content-ref-25954513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061','lexi-content-ref-30857601','lexi-content-ref-25954513'])">Ref</a></span>), but has also been reported following large dose, short-term infusions during surgical anesthesia. PRIS has also been reported with lower-dose infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30857601','lexi-content-ref-26558513','lexi-content-ref-19874582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30857601','lexi-content-ref-26558513','lexi-content-ref-19874582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Catecholamine, corticosteroid, or vasopressor use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061','lexi-content-ref-18664783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061','lexi-content-ref-18664783'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Critical illness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High fat, low carbohydrate intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Inborn error of fatty acid oxidation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464061','lexi-content-ref-24491974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464061','lexi-content-ref-24491974'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18664783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18664783'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased oxygen delivery to tissues</p>
<p style="text-indent:-2em;margin-left:6em;">• Sepsis</p>
<p style="text-indent:-2em;margin-left:6em;">• Serious neurological injury</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F214549"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, asystole, atrial fibrillation, atrial premature contractions, atrioventricular block, bigeminy, bundle branch block, chest pain, depression of ST segment on ECG, edema, extrasystoles, flushing, hypertension, ischemic heart disease, low cardiac output, right heart failure, supraventricular tachycardia, syncope, tachycardia, ventricular fibrillation, ventricular premature contractions, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, hyperglycemia, hyperkalemia, hyperlipidemia, hypomagnesemia<b>,</b> respiratory acidosis (during weaning), serum hyperosmolarity</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, diarrhea, hiccups, intestinal obstruction, nausea, parotid gland enlargement, sialorrhea, sore throat (burning), vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Oliguria, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic components of blood, hemorrhage, leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site, erythema at injection site, injection-site phlebitis, injection-site pruritus, itching at injection site, pain at injection site (includes stinging), skin discoloration at injection site, urticaria at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, abnormality in thinking, anticholinergic syndrome, anxiety, asthenia, atypical sexual behavior, awareness under anesthesia without pain, chills, confusion, delirium, depression, dizziness, drowsiness, emotional lability, euphoria, fatigue, hallucination, headache, hypertonia, hypotonia, hysteria, insomnia, intracranial hypertension, neuropathy, pain, paresthesia, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm, limb pain, muscle rigidity, myalgia, neck stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, conjunctival hyperemia, diplopia, eye pain, nystagmus disorder, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Airway obstruction, apnea, bronchospasm, cough, decreased lung function, dyspnea, hyperventilation, hypoventilation, pharyngitis, sneezing, tachypnea, wheezing</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Baumgarten 2021), ECG abnormality (shortening of the QT interval) (Erdil 2009), hypotension (Baumgarten 2021), phlebitis, prolonged QT interval on ECG (Kim 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypertriglyceridemia (Corrado 2020), metabolic acidosis (Chukwuemeka 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (Farzana 2022), pancreatitis (Asghar 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cloudy urine (including urate crystalluria) (Baumgarten 2021), urine discoloration (green) (Baumgarten 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Koul 2011), angioedema (You 2012), infusion-related reaction (propofol-related infusion syndrome) (Krajčová 2015), nonimmune anaphylaxis (McHale 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Venous thrombosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell (Farzana 2022), anosmia (Farzana 2022), myoclonus (including perioperative; including seizure and opisthotonos) (Tam 2009), neurotoxicity (neuroexcitatory reaction [propofol “frenzy”]; including abnormal eye movements, agitation, clonus, dystonia, impaired consciousness, involuntary body movements [bucking, jerking, and thrashing], shivering, tremor) (Panchamia 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Zarovnaya 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchoconstriction (Nishiyama 2001), hypoxia (Hanna 1998), pulmonary edema (Waheed 2014)</p></div>
<div class="block coi drugH1Div" id="F214563"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to propofol or any component of the formulation; hypersensitivity to eggs, egg products, soybeans, or soy products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the manufacturer's labeling lists egg allergy as a contraindication, available studies (mostly retrospective) and an American Academy of Allergy, Asthma, and Immunology statement have suggested that propofol may be used safely in soy- or egg-allergic patients (AAAAI [Lieberman 2015]; AAAAI 2019; Asserhøj 2016; Dziedzic 2016; Murphy 2011). In patients with more severe soy or egg allergy, consider the use of an alternative anesthetic or a small trial dose of propofol prior to full dose administration (Johnson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindication (not in US labeling): Hypersensitivity to lipid emulsions; sedation of children ≤18 years of age receiving intensive care.</p></div>
<div class="block war drugH1Div" id="F214546"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reaction: Transient local pain may occur during IV injection; lidocaine 1% solution may be administered prior to administration or may be added to propofol immediately prior to administration to reduce pain associated with injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: Use with caution in patients with increased intracranial pressure or impaired cerebral circulation; propofol may cause substantial decreases in mean arterial pressure with subsequent decreases in cerebral perfusion pressure; to minimize risk, consider continuous infusion or administer as a slow bolus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection risk: Propofol vials and prefilled syringes have the potential to support the growth of various microorganisms despite product additives intended to suppress microbial growth. To limit the potential for contamination, strictly adhere to recommendations in product labeling for handling and administering propofol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with respiratory disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of epilepsy or seizures; seizure may occur during recovery phase.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Opioids: Concomitant use may lead to increased sedative or anesthetic effects of propofol, more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output; lower doses of propofol may be needed. In addition, fentanyl may cause serious bradycardia when used with propofol in pediatric patients. Alfentanil use with propofol has precipitated seizure activity in patients without any history of epilepsy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edetate disodium: Some formulations contain edetate disodium which may lead to decreased zinc levels in patients with prolonged therapy (&gt;5 days) or a predisposition to zinc deficiency (eg, burns, diarrhea, or sepsis). A holiday from propofol infusion should take place after 5 days of therapy to allow for evaluation and necessary replacement of zinc.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfites: Some formulations may contain sulfites.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt discontinuation: Avoid abrupt discontinuation prior to weaning or daily wake up assessments. Abrupt discontinuation can result in rapid awakening, anxiety, agitation, and resistance to mechanical ventilation; wean the infusion rate so the patient awakens slowly. Discontinue opioids and paralytic agents prior to weaning. Long-term infusions can result in some tolerance; taper propofol infusions to prevent withdrawal.</p>
<p style="text-indent:-2em;margin-left:4em;">• Analgesic supplementation: Propofol lacks analgesic properties; pain management requires specific use of analgesic agents, at effective dosages, propofol must be titrated separately from the analgesic agent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: Use requires careful patient monitoring, should only be used by experienced personnel who are not actively engaged in the procedure or surgery. If used in a nonintubated and/or nonmechanically ventilated patient, qualified personnel and appropriate equipment for rapid institution of respiratory and/or cardiovascular support must be immediately available. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with deep anesthesia. Consult local regulations and individual institutional policies and procedures.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878611"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus’ brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Use extreme caution when using for refractory status epilepticus because higher doses are often required to control seizures for an extended period of time (in pediatric patients: doses &gt;65 mcg/kg/minute [4 mg/kg/hour] for &gt;48 hours) which may increase risk for propofol-related infusion syndrome (NCS [Brophy 2012]). Fatal cardiac failure has also been reported with concurrent ketogenic diet and propofol therapy (Baumeister 2004).</p></div>
<div class="block foc drugH1Div" id="F214558"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprivan: 100 mg/10 mL (10 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL); 1000 mg/100 mL (100 mL) [contains edetate (edta) disodium, egg phospholipids (egg lecithin), glycerin, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg/100 mL (100 mL); 200 mg/20 mL (20 mL); 500 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprivan: 200 mg/20 mL (20 mL) [contains edetate (edta) disodium, egg phospholipids (egg lecithin), soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg/100 mL (100 mL); 200 mg/20 mL (20 mL [DSC]); 500 mg/50 mL (50 mL)</p></div>
<div class="block geq drugH1Div" id="F214542"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323734"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Diprivan Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $0.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/100 mL (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Propofol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/20 mL (per mL): $0.14 - $0.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $0.14 - $0.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/100 mL (per mL): $0.14 - $0.36</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868059"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diprivan: 10 mg/mL (20 mL, 50 mL, 100 mL) [contains edetate (edta) disodium, egg phosphatides, soybean oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (20 mL, 50 mL, 100 mL)</p></div>
<div class="block adip drugH1Div" id="F53568355"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Propofol injection contains ∼0.1 g of fat/mL (1.1 kcal/mL).</p></div>
<div class="block admp drugH1Div" id="F52613710"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult local regulations and individual institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Propofol 1% (10 mg/mL) (eg, Diprivan): Strict aseptic technique must be maintained in handling. Shake emulsion well before use. May be administered undiluted or may be further diluted with D5W. Do not administer via filter with &lt;5-micron pore size. Do not administer through the same IV catheter with blood or plasma. Tubing and any unused portions of propofol vials should be discarded after 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">To reduce pain associated with bolus injection, use larger veins of forearm or antecubital fossa; lidocaine IV (1 mL of a 1% solution) may also be used prior to administration or lidocaine may be added to propofol immediately before administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Induction: Administer bolus doses over 20 to 30 seconds.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: Administer at a concentration of 2 to 10 mg/mL as intermittent bolus injection at prescribed rate or as a continuous IV infusion via an infusion pump.</p></div>
<div class="block adm drugH1Div" id="F214560"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer intermittent bolus or by continuous IV infusion. Prior to use, consult local/state regulations and institutional policies and procedures regarding administration and monitoring requirements. Strict aseptic technique must be maintained in handling although a preservative has been added. Do not use if contamination is suspected. Do not administer through the same IV catheter with blood or plasma. Tubing and any unused portions of propofol vials should be discarded after 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">To reduce pain associated with injection, use larger veins of forearm or antecubital fossa; lidocaine IV (1 mL of a 1% solution) may also be used prior to administration or it may be added to propofol immediately before administration in a quantity not to exceed 20 mg lidocaine per 200 mg propofol. Do not use filter &lt;5 micron for administration.</p></div>
<div class="block sts drugH1Div" id="F214576"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store between 4°C to 25°C (40°F to 77°F); refrigeration is not required. Do not freeze. Shake well before use. Withdraw from vial into a syringe immediately after sterile vented spike inserted. Administration should begin immediately and completed within 12 hours after the vial has been opened. Do not use if there is evidence of excessive creaming or aggregation, large visible droplets, or separation of phases of emulsion.</p></div>
<div class="block usep drugH1Div" id="F53568564"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Induction of general anesthesia (FDA approved in ages ≥3 years and adults); maintenance of general anesthesia (FDA approved in ages ≥2 months and adults); initiation and maintenance of monitored anesthesia care sedation (FDA approved in adults); sedation of intubated, mechanically ventilated ICU patients (FDA approved in adults); combined sedation and regional anesthesia (FDA approved in adults); has also been used for treatment of refractory status epilepticus and procedural sedation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Consult local regulations and individual institutional policies and procedures.</p></div>
<div class="block mst drugH1Div" id="F214636"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diprivan may be confused with Diflucan, Ditropan</p>
<p style="text-indent:-2em;margin-left:4em;">Propofol may be confused with fospropofol</p>
<p style="text-indent:-2em;margin-left:4em;">Propofol may be confused with bupivacaine (liposomal) due to similar white, milky appearance.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Propofol is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided at doses &gt;4 mg/kg/hour for &gt;48 hours due to risk of propofol-related infusion syndrome; the incidence is higher in children and adolescents than adults because of higher relative doses of propofol required, especially in status epilepticus (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Propofol may be confused with bupivacaine liposome injectable suspension (Exparel) in operating rooms and other surgical areas due to their similar white, milky appearance especially when prepared in syringes. Bupivacaine liposome injectable suspension (Exparel) is intended only for administration via infiltration into the surgical site (and <b>not </b>for systemic use). Confusion with propofol may lead to accidental intravenous administration of Exparel instead of the intended propofol. Therefore, to avoid potential confusion ISMP recommends that all vials be separated when stocked in common areas and all prepared syringes be labeled.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F214621"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F214551"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: May enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or tonic clonic seizures.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May diminish the therapeutic effect of Propofol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Carbetocin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Propofol may enhance the bradycardic effect of Ceritinib. Propofol may enhance the QTc-prolonging effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Also monitor for QTc prolongation and ventricular arrhythmia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of Propofol. Propofol may enhance the QTc-prolonging effect of DroPERidol. Management: Consider dose reductions of droperidol or propofol during coadministration due to additive effects on CNS depression. Also monitor for QTc prolongation and ventricular arrhythmia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Propofol may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Etelcalcetide.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Propofol may enhance the CNS depressant effect of FentaNYL.  Management: Consider alternatives to this combination when possible. If the combination is used, monitor more closely for bradycardia, apnea, and excessive CNS depression. Propofol induction dose requirements may be reduced. Pediatric patients may be at greater risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Propofol may enhance the arrhythmogenic effect of Fexinidazole. Propofol may enhance the QTc-prolonging effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the therapeutic effect of Propofol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Oxytocin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Propofol may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Propofol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Propofol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May enhance the hypotensive effect of Propofol. Management: Avoid this combination if possible. Use of propofol in a patient who has been taking rifampin may result in clinically significant hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the therapeutic effect of Propofol. Management: Decrease the propofol dose and monitor for sedation and cardiorespiratory depression during coadministration with valproate products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F214579"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Edetate disodium, an ingredient of propofol emulsion, may lead to decreased zinc levels in patients on prolonged therapy (&gt;5 days) or those predisposed to deficiency (burns, diarrhea, and/or major sepsis). Management: Zinc replacement therapy may be needed.</p></div>
<div class="block dic drugH1Div" id="F214567"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Propofol is formulated in an oil-in-water emulsion. If on parenteral nutrition, may need to adjust the amount of lipid infused. Propofol emulsion contains 1.1 kcal/mL. Soybean fat emulsion is used as a vehicle for propofol. Formulations also contain egg phospholipids (egg lecithin) and glycerol.</p></div>
<div class="block pri drugH1Div" id="F214566"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Propofol crosses the placenta and may be associated with neonatal CNS and respiratory depression. Monitor exposed neonates for hypotonia and sedation.</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Evaluate benefits and potential risks of fetal exposure to propofol when duration of surgery is expected to be &gt;3 hours (Olutoye 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Propofol has been used as an induction agent in cases where general anesthesia is needed for cesarean delivery (ACOG 209 2019; Devroe 2015).</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that pregnant patients should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 775 2019).</p></div>
<div class="block mopp drugH1Div" id="F53568555"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cardiac monitor, blood pressure, heart rate, oxygen saturation (during monitored anesthesia care sedation), arterial blood gas (with prolonged infusions). With continuous IV infusions outside of short procedures (eg, ICU sedation), monitor for metabolic acidosis, hyperkalemia, serum triglycerides concentrations, rhabdomyolysis or elevated CPK, hepatomegaly, and progression of cardiac and renal failure.</p>
<p style="text-indent:-2em;margin-left:2em;">Diprivan: Monitor zinc levels in patients predisposed to deficiency (burns, diarrhea, major sepsis) or after 5 days of treatment.</p></div>
<div class="block pha drugH1Div" id="F214545"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Propofol is a short-acting, lipophilic intravenous general anesthetic. The drug is unrelated to any of the currently used barbiturate, opioid, benzodiazepine, arylcyclohexylamine, or imidazole intravenous anesthetic agents. Propofol causes global CNS depression, presumably through agonism of GABA<sub>A</sub> receptors and perhaps reduced glutamatergic activity through NMDA receptor blockade. </p></div>
<div class="block phk drugH1Div" id="F214562"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Anesthetic: Bolus infusion (dose dependent): 9 to 51 seconds (average 30 seconds)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: 3 to 10 minutes depending on the dose, rate and duration of administration; with prolonged use (eg, 10 days ICU sedation), propofol accumulates in tissues and redistributes into plasma when the drug is discontinued, so that the time to awakening (duration of action) is increased; however, if dose is titrated on a daily basis, so that the minimum effective dose is utilized, time to awakening may be within 10 to 15 minutes even after prolonged use</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Large volume of distribution; highly lipophilic ; V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 4 to 12 years: 5 to 10 L/kg </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: 2 to 10 L/kg; after a 10-day infusion, V<sub>d</sub> approaches 60 L/kg; decreased in the elderly</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 97% to 99% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to water-soluble sulfate and glucuronide conjugates (~50%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Biphasic: Initial: 40 minutes; Terminal: 4 to 7 hours (after 10-day infusion, may be up to 1 to 3 days) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~88% as metabolites, 40% as glucuronide metabolite); feces (&lt;2%) </p></div>
<div class="block phksp drugH1Div" id="F51220141"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: With increasing age, the dose requirement decreases because of occurrence of higher peak plasma concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic hypothermia: Hypothermia (33°C to 34°C or 91.4°F to 93.2°F) is associated with a decrease in total body clearance (~23%) and an increase in plasma concentrations (~28%), likely as a result of reduced hepatic blood flow and/or reduced intercompartmental clearance (Bjelland 2013; Leslie 1995). During the rewarming phase, plasma concentrations decrease (~12% or ~3% decrease for every centigrade increase in core body temperature from 33°C to 37°C [91.4°F to 98.6°F]) (Bjelland 2014).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F214568"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Provive</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dubernard | Fresofol mct | Gobbifol | Oleo lax | Profol | Propofol Abbott | Propofol Baxter | Propofol gemepe | Propofol gray | Propofol lipuro | Propofol northia | Propovan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol Baxter | Propofol claris | Propofol lipuro | Propofol ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol mct/lct | Propofol bc | Propofol lipuro | Provive | Provive mct lct | Recofol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Pofol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol EG | Propofol fresenius | Propofol sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dormofol | Plofed | Profol | Propofol sandoz</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Lipuro | Mayoprofol | Oponap | Profolen | Pronest | Propoabbott | Propotil | Propovan | Provive</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Disoprivan | Propofol lipuro | Propofol mct fresenius</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Diprivan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Di shi ning | Propofol fresenius | Recofol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blofop | Diprivan | Fresofol | Mayoprofol | Nirfol | Oleo lax | Profol | Rapifol | Serafol | Sevofol | Spiva mct lct | Troypofol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Propofol mct fresenius | Recofol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Disoprivan | Klimofol | Propofol claris | Propofol fresenius | Propofol Hexal | Propofol lipuro | Propofol ratiopharm | Recofol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propovan | Proxofol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fiprolif | Propofol lipuro | Provive</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Propofol claris | Propofol lipuro | Propofol norameda | Propoven</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Pofol | Propofol lipuro | Recofol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Ivofol | Propofol Abbott | Propofol Baxter | Propofol fresenius | Propofol lipomed | Propofol lipuro | Propofol rovi | Propofol sandoz | Recofol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Spiva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Profast | Propofol Abbott | Propofol Alpharma | Propofol fresenius kabi | Propofol lipuro | Propolipid | Recofol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol Baxter | Propofol bioq | Propofol dakota | Propofol fresenius | Propofol lipuro | Propofol panpharma | Propofol pf</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Propoven</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Propofol mct/lct fresenius | Propofol/Alvia | Propofol/baxter | Propofol/fresenius | Recofol | Spiva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Propofol fresenius | Propofol lipuro</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Propofol fresenius | Propofol lipuro | Propofol mct/lct fresenius | Recofol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anesticap | Diprivan | Fresofol | Nupovel | Proanes | Propofol lipuro | Recofol | Recofol n | Safol | Trivam</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Propoven</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cleofol | Critifol | Diprivan | Epurol | Fresofol | Fresofol mct/lct | Hyprovan | Neorof | Popoglan | Profol | Propovan | Prosthetik | Rapifol | Rofol | Troypofol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol b.braun | Propofol kabi | Rapiva | Ripol | Unifol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Safol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Propofol Abbott | Propofol Fuji | Propofol Hospira | Propofol Maruishi | Propofol Merck</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dormifor | Galaxy's propofol | Neorof | Pofol | Propofol lipuro | Propovan | Provive</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anepol | Aquafol | Diprivan | Fresofol | Pofol | Propofol Lipro | Provive</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresenius propoven | Propofol lipuro | Recofol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dormifor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Propofol claris | Propofol lipuro | Propofol norameda | Propoven | Provive</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diprivan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Propofol claris | Propofol lipuro | Propoven</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Diprivan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Diovist | Diprivan | Indufol | Lofol | Moveloc | Neleprit | Plofed | Prigadef | Propofol lipuro | Quipro | Rachechi | Recofol | Vitenaltec | Xendta | Xenprof</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Fresofol mct/lct | Propofol lipuro | Spiva | Troypofol</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Propofol lipuro | Troypofol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol farmaconetwork | Propofol fresenius | Propofol Genthon | Propofol lipuro | Propofol mct/lct fresenius</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol braun | Propofol lipuro | Propolipid | Recofol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Provive | Provive mct lct | Recofol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Nirfol | Propovan | Prosafe | Troypofol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Fresofol | Iv pro | Lexofol | Lipuro | Neorof | Operol | Profogen | Spiva with mct lct</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Fresofol | Pofol | Propofol lipuro</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Abbofol | Anesia | Diprivan | Disoprivan | Plofed | Propofol fresenius | Propofol lipuro | Propofol mct/lct fresenius | Propofol norameda | Propofol sandoz | Provive | Troypofol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresenius propoven | Propoven</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Propofol Alpharma | Propofol aps | Propofol Genthon | Propofol lipuro | Propofol norameda | Recofol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dorminox | Propofol claris</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol 1% MCT/LCT Fresenius | Propofol-Lipuro | Provive | Recofol EDTA | Recofol N</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Profast | Propofol mct/lct fresenius</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Pofol | Proanes | Propofol kabi | Propofol lipuro | Propofol medargo | Propofol novo | Propovan | Provive | Recofol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propoven | Recofol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Profast | Propofol Abbott | Propofol Actavis | Propofol fresenius | Propofol lipuro | Propofol sandoz | Propolipid | Recofol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Fresofol | Propofol lipuro | Recofol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anesia | Diprivan | Propofol lipuro | Propoven</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Propofol lipuro | Propofol mct/lct fresenius | Recofol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Anepol | Anesvan | Diprivan | Fresofol | Fresofol mct/lct | Pofol | Propofol Abbott | Propofol lipuro | Recofol | Troypofol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Pms propofol | Propofol fresenius | Propofol lipuro</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Dormofol | Pofol | Propofol Abbott | Propofol Genthon | Propofol pf</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anesvan | Diprivan | Diprofen | Fresofol | Pofol | Propofol lipuro | Recofol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Diprofol | Diprofol edta | Profol | Propofol kabi | Propofol lipuro | Propophol | Recofol | Rekofol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fresenius propoven | Proanes mct/lct | Provive</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Diprivan | Ivofol | Oleo lax | Pofol | Propovan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anespro | Diprivan | Diprivan aventis | Profol | Profol spiva | Propowell | Spiva</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">B. braun propofol | Diprivan | Propoven | Provive</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Troypofol</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Fresenius propoven</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAAAI.1">
<a name="AAAAI.1"></a>American Academy of Allergy, Asthma, and Immunology. Soy-allergic and egg-allergic patients can safely receive anesthesia. Updated September 28, 2020. Accessed August 16, 2021. https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Allergies/soy-egg-anesthesia
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22401952">
<a name="22401952"></a>Andolfatto G, Abu-Laban RB, Zed PJ, et al. Ketamine-propofol combination (ketofol) versus propofol alone for emergency department procedural sedation and analgesia: a randomized double-blind trial. <i>Ann Emerg Med</i>. 2012;59(6):504-12.e1-2. doi:10.1016/j.annemergmed.2012.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22401952/pubmed" id="22401952" target="_blank">22401952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31797395">
<a name="31797395"></a>Araújo AM, Machado H, de Pinho PG, Soares-da-Silva P, Falcão A. Population pharmacokinetic-pharmacodynamic modeling for propofol anesthesia guided by the bispectral index (BIS). <i>J Clin Pharmacol</i>. 2019. doi:10.1002/jcph.1560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/31797395/pubmed" id="31797395" target="_blank">31797395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29159892">
<a name="29159892"></a>Araújo AM, Machado HS, Falcão AC, Soares-da-Silva P. Reliability of body-weight scalars on the assessment of propofol induction dose in obese patients. <i>Acta Anaesthesiol Scand</i>. 2018;62(4):464-473. doi:10.1111/aas.13039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/29159892/pubmed" id="29159892" target="_blank">29159892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31283535">
<a name="31283535"></a>Asghar MU, Cheema HA, Tanveer K, Leinwand J. Propofol infusion and acute pancreatitis: a review. <i>Am J Ther</i>. 2020;27(4):e371-e374. doi:10.1097/MJT.0000000000001021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/31283535/pubmed" id="31283535" target="_blank">31283535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26675952">
<a name="26675952"></a>Asserhøj LL, Mosbech H, Krøigaard M, Garvey LH. No evidence for contraindications to the use of propofol in adults allergic to egg, soy or peanut.<i> Br J Anaesth</i>. 2016;116(1):77-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/26675952/pubmed" id="26675952" target="_blank">26675952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33529424">
<a name="33529424"></a>Bagley L, Kordun A, Sinnott S, Lobo K, Cravero J. Food allergy history and reaction to propofol administration in a large pediatric population. <i>Paediatr Anaesth</i>. 2021;31(5):570-577. doi:10.1111/pan.14147<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/33529424/pubmed" id="33529424" target="_blank">33529424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med</i>. 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.1">
<a name="Expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24529993">
<a name="24529993"></a>Bassi E, Ferreira CB, Macedo E, Malbouisson LM. Recurrent clotting of dialysis filter associated with hypertriglyceridemia induced by propofol. <i>Am J Kidney Dis</i>. 2014;63(5):860-861. doi:10.1053/j.ajkd.2014.01.417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24529993/pubmed" id="24529993" target="_blank">24529993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15328567">
<a name="15328567"></a>Baumeister FAM, Oberhoffer R, Liebhaber GM, et.al. Fatal propofol infusion syndrome in association with ketogenic diet. <i>Neuropediatrics</i>. 2004;35: 250-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/15328567/pubmed" id="15328567" target="_blank">15328567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34309948">
<a name="34309948"></a>Baumgarten A, Newton M. Propofol-induced uric acid crystals: a case of cloudy urine. <i>Paediatr Anaesth</i>. 2021;31(10):1132-1133. doi:10.1111/pan.14260<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/34309948/pubmed" id="34309948" target="_blank">34309948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21958025">
<a name="21958025"></a>Bedirli N, Egritas O, Cosarcan K, Bozkirli F. A comparison of fentanyl with tramadol during propofol-based deep sedation for pediatric upper endoscopy. <i>Paediatr Anaesth</i>. 2012;22(2):150-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/21958025/pubmed" id="21958025" target="_blank">21958025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21233125">
<a name="21233125"></a>Belso N, Kui R, Szegesdi I, et al. Propofol and fentanyl induced perioperative anaphylaxis. <i>Br J Anaesth</i>. 2011;106(2):283-284. doi:10.1093/bja/aeq384<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/21233125/pubmed" id="21233125" target="_blank">21233125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390417">
<a name="17390417"></a>Bendel S, Ruokonen E, Pölönen P, Uusaro A. Propofol causes more hypotension than etomidate in patients with severe aortic stenosis: a double-blind, randomized study comparing propofol and etomidate. <i>Acta Anaesthesiol Scand</i>. 2007;51(3):284-289. doi:10.1111/j.1399-6576.2006.01206.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/17390417/pubmed" id="17390417" target="_blank">17390417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31849243">
<a name="31849243"></a>Benken S, Madrzyk E, Chen D, et al. Hemodynamic effects of propofol and dexmedetomidine in septic patients without shock. <i>Ann Pharmacother</i>. 2020;54(6):533-540. doi:10.1177/1060028019895502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/31849243/pubmed" id="31849243" target="_blank">31849243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19858894">
<a name="19858894"></a>Birkholz T, Eckardt G, Renner S, et al. Green breast milk after propofol administration. <i>Anesthesiology</i>. 2009;111(5):1168-1169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19858894/pubmed" id="19858894" target="_blank">19858894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23115086">
<a name="23115086"></a>Bjelland TW, Klepstad P, Haugen BO, Nilsen T, Dale O. Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. <i>Drug Metab Dispos.</i> 2013;41(1):214-223. doi:10.1124/dmd.112.045567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/23115086/pubmed" id="23115086" target="_blank">23115086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24611449">
<a name="24611449"></a>Bjelland TW, Klepstad P, Haugen BO, Nilsen T, Salvesen O, Dale O. Concentrations of remifentanil, propofol, fentanyl, and midazolam during rewarming from therapeutic hypothermia. <i>Acta Anaesthesiol Scand</i>. 2014;58(6):709-715. doi:10.1111/aas.12300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24611449/pubmed" id="24611449" target="_blank">24611449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caro.1">
<a name="Caro.1"></a>Caro D. Induction agents for rapid sequence intubation in adults for emergency medicine and critical care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30101390">
<a name="30101390"></a>Chidambaran V, Costandi A, D'Mello A. Correction to: Propofol: a review of its role in pediatric anesthesia and sedation. <i>CNS Drugs</i>. 2018;32(9):873. doi:10.1007/s40263-018-0561-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30101390/pubmed" id="30101390" target="_blank">30101390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26290263">
<a name="26290263"></a>Chidambaran V, Costandi A, D'Mello A. Propofol: a review of its role in pediatric anesthesia and sedation [published correction appears in <i>CNS Drugs</i>. 2018;32(9):873]. <i>CNS Drugs</i>. 2015;29(7):543-563. doi:10.1007/s40263-015-0259-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/26290263/pubmed" id="26290263" target="_blank">26290263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17061643">
<a name="17061643"></a>Chukwuemeka A, Ko R, Ralph-Edwards A. Short-term low-dose propofol anaesthesia associated with severe metabolic acidosis. <i>Anaesth Intensive Care</i>. 2006;34(5):651-655. doi:10.1177/0310057X0603400503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/17061643/pubmed" id="17061643" target="_blank">17061643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18225970">
<a name="18225970"></a>Corbett SM, Montoya ID, Moore FA. Propofol-related infusion syndrome in intensive care patients. <i>Pharmacotherapy</i>. 2008;28(2):250-258. doi:10.1592/phco.28.2.250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18225970/pubmed" id="18225970" target="_blank">18225970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33274340">
<a name="33274340"></a>Corrado MJ, Kovacevic MP, Dube KM, Lupi KE, Szumita PM, DeGrado JR. The incidence of propofol-induced hypertriglyceridemia and identification of associated risk factors. <i>Crit Care Explor</i>. 2020;2(12):e0282. doi:10.1097/CCE.0000000000000282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/33274340/pubmed" id="33274340" target="_blank">33274340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cravero.1">
<a name="Cravero.1"></a>Cravero JP, Kaplan RF, Landrigan-Ossar M, Coté CJ. Sedation for diagnostic and therapeutic procedures outside the operating room. In: Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:chap. 48.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589672">
<a name="2589672"></a>Dailland P, Cockshott ID, Lirzin JD, et al. Intravenous propofol during cesarean section: placental transfer, concentrations in breast milk, and neonatal effects. A preliminary study. <i>Anesthesiology</i>. 1989;71(6):827-834.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/2589672/pubmed" id="2589672" target="_blank">2589672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31932363">
<a name="31932363"></a>de Kort EHM, Prins SA, Reiss IKM, et al. Propofol for endotracheal intubation in neonates: a dose-finding trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2020a;105(5):489-495. doi:10.1136/archdischild-2019-318474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/31932363/pubmed" id="31932363" target="_blank">31932363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32248549">
<a name="32248549"></a>de Kort EHM, Twisk JWR, van T Verlaat EPG, Reiss IKM, Simons SHP, van Weissenbruch MM. Propofol in neonates causes a dose-dependent profound and protracted decrease in blood pressure. <i>Acta Paediatr</i>. 2020b;109(12):2539-2546. doi:10.1111/apa.15282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32248549/pubmed" id="32248549" target="_blank">32248549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1642359">
<a name="1642359"></a>de Leon-Casasola OA, Weiss A, Lema MJ. Anaphylaxis due to propofol. <i>Anesthesiology</i>. 1992;77(2):384-386. doi:10.1097/00000542-199208000-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/1642359/pubmed" id="1642359" target="_blank">1642359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27199311">
<a name="27199311"></a>de Wit F, van Vliet AL, de Wilde RB, et al. The effect of propofol on haemodynamics: cardiac output, venous return, mean systemic filling pressure, and vascular resistances. <i>Br J Anaesth</i>. 2016;116(6):784-789. doi:10.1093/bja/aew126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/27199311/pubmed" id="27199311" target="_blank">27199311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7639382">
<a name="7639382"></a>Deutschman CS, Harris AP, Fleisher LA. Changes in heart rate variability under propofol anesthesia: a possible explanation for propofol-induced bradycardia. <i>Anesth Analg</i>. 1994;79(2):373-377. doi:10.1213/00000539-199408000-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/7639382/pubmed" id="7639382" target="_blank">7639382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16185179">
<a name="16185179"></a>Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. <i>Pharmacotherapy. </i>2005;25(10):1348-1352. doi:10.1592/phco.2005.25.10.1348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/16185179/pubmed" id="16185179" target="_blank">16185179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25827280">
<a name="25827280"></a>Devroe S, Van de Velde M, Rex S. General anesthesia for caesarean section. <i>Curr Opin Anaesthesiol</i>. 2015;28(3):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/25827280/pubmed" id="25827280" target="_blank">25827280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464061">
<a name="21464061"></a>Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. <i>J Intensive Care Med</i>. 2011;26(2):59-72. doi:10.1177/0885066610384195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/21464061/pubmed" id="21464061" target="_blank">21464061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30268185">
<a name="30268185"></a>Dietrich SK, Mixon MA, Rogoszewski RJ, et al. Hemodynamic effects of propofol for induction of rapid sequence intubation in traumatically injured patients. <i>Am Surg</i>. 2018;84(9):1504-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30268185/pubmed" id="30268185" target="_blank">30268185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprivan.1">
<a name="Diprivan.1"></a>Diprivan (propofol) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diprivan.2">
<a name="Diprivan.2"></a>Diprivan (propofol) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18973642">
<a name="18973642"></a>Douglas RJ, Cadogan M. Cardiac arrhythmia during propofol sedation. <i>Emerg Med Australas</i>. 2008;20(5):437-440. doi:10.1111/j.1742-6723.2008.01126.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18973642/pubmed" id="18973642" target="_blank">18973642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.1">
<a name="Drislane.1"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10794344">
<a name="10794344"></a>Ducart AR, Watremez C, Louagie YA, Collard EL, Broka SM, Joucken KL. Propofol-induced anaphylactoid reaction during anesthesia for cardiac surgery. <i>J Cardiothorac Vasc Anesth</i>. 2000;14(2):200-201. doi:10.1016/s1053-0770(00)90020-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/10794344/pubmed" id="10794344" target="_blank">10794344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27145556">
<a name="27145556"></a>Dziedzic A. Is Propofol Safe For Food Allergy Patients? A Review of the Evidence. <i>SAAD Dig</i>. 2016;32:23-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/27145556/pubmed" id="27145556" target="_blank">27145556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37196592">
<a name="37196592"></a>Engstrom K, Brown CS, Mattson AE, Lyons N, Rech MA. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. <i>Am J Emerg Med</i>. 2023;70:19-29. doi:10.1016/j.ajem.2023.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/37196592/pubmed" id="37196592" target="_blank">37196592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19225403">
<a name="19225403"></a>Erdil F, Demirbilek S, Begec Z, Ozturk E, Ersoy MO. Effects of propofol or etomidate on QT interval during electroconvulsive therapy. <i>J ECT</i>. 2009;25(3):174-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19225403/pubmed" id="19225403" target="_blank">19225403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32513237">
<a name="32513237"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. <i>Crit Care</i>. 2020;24(1):315. doi:10.1186/s13054-020-03040-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32513237/pubmed" id="32513237" target="_blank">32513237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35075034">
<a name="35075034"></a>Farzana N, Tewari P, Sureka S, Dixit A. Parosmia and dysgeusia after intravenous propofol-based general anesthesia: a case report. <i>Ann Card Anaesth</i>. 2022;25(1):112-115. doi:10.4103/aca.ACA_93_21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/35075034/pubmed" id="35075034" target="_blank">35075034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8368555">
<a name="8368555"></a>Fassoulaki A, Farinotti R, Servin F, et al, "Chronic Alcoholism Increases the Induction Dose of Propofol in Humans," <i>Anesth Analg</i>, 1993, 77(3):553-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/8368555/pubmed" id="8368555" target="_blank">8368555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27460905">
<a name="27460905"></a>Ferguson I, Bell A, Treston G, New L, Ding M, Holdgate A. Propofol or ketofol for procedural sedation and analgesia in emergency medicine-the POKER study: a randomized double-blind clinical trial. <i>Ann Emerg Med</i>. 2016;68(5):574-582.e1. doi:10.1016/j.annemergmed.2016.05.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/27460905/pubmed" id="27460905" target="_blank">27460905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18664783">
<a name="18664783"></a>Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in patients with suspected propofol infusion syndrome. <i>Crit Care Med</i>. 2008;36(8):2281-2287. doi:10.1097/CCM.0b013e318180c1eb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18664783/pubmed" id="18664783" target="_blank">18664783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17924915">
<a name="17924915"></a>Gangineni K, Scase AE, and Fearn J, “Propofol and Peanut Allergy,” <i>Anaesthesia</i>, 2007, 62(11):1183-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/17924915/pubmed" id="17924915" target="_blank">17924915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24438649">
<a name="24438649"></a>Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. <i>Ann Emerg Med</i>. 2014;63(2):247-258. doi: 10.1016/j.annemergmed.2013.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24438649/pubmed" id="24438649" target="_blank">24438649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9443502">
<a name="9443502"></a>Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. <i>Neurology</i>. 1998;50(1):301-303. doi:10.1212/wnl.50.1.301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/9443502/pubmed" id="9443502" target="_blank">9443502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30857601">
<a name="30857601"></a>Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. <i>Br J Anaesth.</i> 2019;122(4):448-459. doi:10.1016/j.bja.2018.12.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30857601/pubmed" id="30857601" target="_blank">30857601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1443685">
<a name="1443685"></a>Hermann R, Vettermann J. Change of ectopic supraventricular tachycardia to sinus rhythm during administration of propofol. <i>Anesth Analg</i>. 1992;75(6):1030-1032. doi:10.1213/00000539-199212000-00028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/1443685/pubmed" id="1443685" target="_blank">1443685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15721728">
<a name="15721728"></a>Hidaka S, Kawamoto M, Kurita S, Yuge O. Comparison of the effects of propofol and midazolam on the cardiovascular autonomic nervous system during combined spinal and epidural anesthesia. <i>J Clin Anesth</i>. 2005;17(1):36-43. doi:10.1016/j.jclinane.2004.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/15721728/pubmed" id="15721728" target="_blank">15721728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33528922">
<a name="33528922"></a>Hughes CG, Mailloux PT, Devlin JW, et al. Dexmedetomidine or propofol for sedation in mechanically ventilated adults with sepsis. <i>N Engl J Med</i>. 2021;384(15):1424-1436. doi:10.1056/NEJMoa2024922<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/33528922/pubmed" id="33528922" target="_blank">33528922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18713888">
<a name="18713888"></a>Hume-Smith HV, Sanatani S, Lim J, Chau A, Whyte SD. The effect of propofol concentration on dispersion of myocardial repolarization in children. <i>Anesth Analg</i>. 2008;107(3):806-810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18713888/pubmed" id="18713888" target="_blank">18713888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22436955">
<a name="22436955"></a>Jakob SM, Ruokonen E, Grounds RM, et al; Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. <i>JAMA</i>. 2012;307(11):1151-1160. doi:10.1001/jama.2012.304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22436955/pubmed" id="22436955" target="_blank">22436955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16176118">
<a name="16176118"></a>Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. <i>Clin Pharmacokinet</i>. 2005;44(10):1051-1065. doi:10.2165/00003088-200544100-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/16176118/pubmed" id="16176118" target="_blank">16176118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34309659">
<a name="34309659"></a>Johnson JL, Hawthorne A, Bounds M, Weldon DJ. New perspectives on propofol allergy. <i>Am J Health Syst Pharm</i>. 2021;78(24):2195-2203. doi:10.1093/ajhp/zxab298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/34309659/pubmed" id="34309659" target="_blank">34309659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24233892">
<a name="24233892"></a>Jones GM, Doepker BA, Erdman MJ, Kimmons LA, Elijovich L. Predictors of severe hypotension in neurocritical care patients sedated with propofol. <i>Neurocrit Care</i>. 2014;20(2):270-276. doi:10.1007/s12028-013-9902-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24233892/pubmed" id="24233892" target="_blank">24233892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18717665">
<a name="18717665"></a>Kim DH, Kweon TD, Nam SB, Han DW, Cho WY, Lee JS. Effects of target concentration infusion of propofol and tracheal intubation on QTc interval. <i>Anaesthesia</i>. 2008;63(10):1061-1064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18717665/pubmed" id="18717665" target="_blank">18717665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22174476">
<a name="22174476"></a>Koul A, Jain R, Sood J. A critical incident report: propofol triggered anaphylaxis. <i>Indian J Anaesth</i>. 2011;55(5):530-533. doi:10.4103/0019-5049.89898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22174476/pubmed" id="22174476" target="_blank">22174476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26558513">
<a name="26558513"></a>Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. <i>Crit Care</i>. 2015;19:398. doi:10.1186/s13054-015-1112-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/26558513/pubmed" id="26558513" target="_blank">26558513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10816184">
<a name="10816184"></a>Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. <i>N Engl J Med</i>, 2000;342(20):1471-1477. doi:10.1056/NEJM200005183422002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/10816184/pubmed" id="10816184" target="_blank">10816184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10208230">
<a name="10208230"></a>Kumar AN, Schwartz DE, Lim KG. Propofol-induced pancreatitis: recurrence of pancreatitis after rechallenge. <i>Chest</i>. 1999;115(4):1198-1199. doi:10.1378/chest.115.4.1198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/10208230/pubmed" id="10208230" target="_blank">10208230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379418">
<a name="1379418"></a>Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan). <i>Anesthesiology</i>. 1992;77(2):275-280. doi:10.1097/00000542-199208000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/1379418/pubmed" id="1379418" target="_blank">1379418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11878723">
<a name="11878723"></a>Laxenaire MC, Mertes PM; Groupe d'Etudes des Réactions Anaphylactoïdes Peranesthésiques. Anaphylaxis during anaesthesia. Results of a two-year survey in France. <i>Br J Anaesth</i>. 2001;87(4):549-558. doi:10.1093/bja/87.4.549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/11878723/pubmed" id="11878723" target="_blank">11878723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22787384">
<a name="22787384"></a>Lee SJ, Kim SI, Jung BI, et al. Suspected anaphylactic reaction associated with microemulsion propofol during anesthesia induction. <i>J Korean Med Sci</i>. 2012;27(7):827-829. doi:10.3346/jkms.2012.27.7.827<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22787384/pubmed" id="22787384" target="_blank">22787384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27544138">
<a name="27544138"></a>Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus? <i>Intensive Care Med</i>. 2017;43(4):543-546. doi:10.1007/s00134-016-4501-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/27544138/pubmed" id="27544138" target="_blank">27544138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7726398">
<a name="7726398"></a>Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. <i>Anesth Analg.</i> 1995;80(5):1007-1014. doi:10.1097/00000539-199505000-00027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/7726398/pubmed" id="7726398" target="_blank">7726398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21642950">
<a name="21642950"></a>Liu Q, Kong AL, Chen R, et al. Propofol and arrhythmias: two sides of the coin. <i>Acta Pharmacol Sin</i>. 2011;32(6):817-823. doi:10.1038/aps.2011.42<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/21642950/pubmed" id="21642950" target="_blank">21642950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2605073">
<a name="2605073"></a>McConachie I, Keaveny JP, Healy TE, Vohra S, Million L. Effect of anaesthesia on the QT interval. <i>Br J Anaesth</i>. 1989;63(5):558-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/2605073/pubmed" id="2605073" target="_blank">2605073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1443479">
<a name="1443479"></a>McHale SP, Konieczko K. Anaphylactoid reaction to propofol. <i>Anaesthesia</i>. 1992;47(10):864-865. doi:10.1111/j.1365-2044.1992.tb03150.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/1443479/pubmed" id="1443479" target="_blank">1443479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30158750">
<a name="30158750"></a>McLaughlin DC, Fang DC, Nolot BA, Guru PK. Hypertriglyceridemia causing continuous renal replacement therapy dysfunction in a patient with end-stage liver disease. <i>Indian J Nephrol</i>. 2018;28(4):303-306. doi:10.4103/ijn.IJN_201_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30158750/pubmed" id="30158750" target="_blank">30158750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19337821">
<a name="19337821"></a>McLeay SC, Morrish GA, Kirkpatrick CM, Green B. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. <i>Pharm Res</i>. 2009;26(7):1626-1634. doi:10.1007/s11095-009-9873-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19337821/pubmed" id="19337821" target="_blank">19337821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18361011">
<a name="18361011"></a>McNeill O, Kerridge RK, Boyle MJ. Review of procedures for investigation of anaesthesia-associated anaphylaxis in Newcastle, Australia. <i>Anaesth Intensive Care</i>. 2008;36(2):201-207. doi:10.1177/0310057X0803600210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/18361011/pubmed" id="18361011" target="_blank">18361011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30732981">
<a name="30732981"></a>Miller KA, Andolfatto G, Miner JR, Burton JH, Krauss BS. Clinical practice guideline for emergency department procedural sedation with propofol: 2018 update. <i>Ann Emerg Med.</i> 2019;73(5):470-480. doi:10.1016/j.annemergmed.2018.12.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/30732981/pubmed" id="30732981" target="_blank">30732981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25954513">
<a name="25954513"></a>Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. <i>Crit Care Res Pract</i>. 2015;2015:260385. doi:10.1155/2015/260385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/25954513/pubmed" id="25954513" target="_blank">25954513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32067810">
<a name="32067810"></a>Mudri M, Williams A, Priestap F, Davidson J, Merritt N. Comparison of drugs used for intubation of pediatric trauma patients. <i>J Pediatr Surg</i>. 2020;55(5):926-929. doi:10.1016/j.jpedsurg.2020.01.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32067810/pubmed" id="32067810" target="_blank">32067810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22797405">
<a name="22797405"></a>Muniraj T, Aslanian HR. Hypertriglyceridemia independent propofol-induced pancreatitis. <i>JOP</i>. 2012;13(4):451-453. doi:10.6092/1590-8577/822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22797405/pubmed" id="22797405" target="_blank">22797405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21467558">
<a name="21467558"></a>Murphy A, Campbell DE, Baines D, et al. Allergic reactions to propofol in egg-allergic children. <i>Anesth Analg</i>. 2011;113(1):140-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/21467558/pubmed" id="21467558" target="_blank">21467558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11524333">
<a name="11524333"></a>Nishiyama T, Hanaoka K. Propofol-induced bronchoconstriction: two case reports. <i>Anesth Analg</i>. 2001;93(3):645-646. doi:10.1097/00000539-200109000-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/11524333/pubmed" id="11524333" target="_blank">11524333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16765143">
<a name="16765143"></a>Nitsun M, Szokol JW, Saleh HJ, et al. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. <i>Clin Pharmacol Ther</i>. 2006;79(6):549-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/16765143/pubmed" id="16765143" target="_blank">16765143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888583">
<a name="28888583"></a>Olutoye OA, Baker BW, Belfort MA, Olutoye OO. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. <i>Am J Obstet Gynecol</i>. 2018;218(1):98-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/28888583/pubmed" id="28888583" target="_blank">28888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35299226">
<a name="35299226"></a>Panchamia JK, Amundson AW, Demirci O, Braksick SA, Wijdicks EF. A case report of "propofol frenzy": anesthetic considerations for a severe propofol-induced neuroexcitation reaction. <i>A A Pract</i>. 2022;16(3):e01569. doi:10.1213/XAA.0000000000001569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/35299226/pubmed" id="35299226" target="_blank">35299226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24491974">
<a name="24491974"></a>Parness J, Savard M, Turgeon AF. Propofol-related infusion syndrome heralding a mitochondrial disease: case report. <i>Neurology</i>. 2014;82(5):461. doi:10.1212/01.wnl.0000443933.18269.20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24491974/pubmed" id="24491974" target="_blank">24491974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11442156">
<a name="11442156"></a>Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. <i>Epilepsia</i>. 2001;42(3):380–386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/11442156/pubmed" id="11442156" target="_blank">11442156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29922905">
<a name="29922905"></a>Rai S, Drislane FW. Treatment of refractory and super-refractory status epilepticus. <i>Neurotherapeutics</i>. 2018;15(3):697-712. doi:10.1007/s13311-018-0640-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/29922905/pubmed" id="29922905" target="_blank">29922905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19514884">
<a name="19514884"></a>Riezzo I, Centini F, Neri M, et al. Brugada-like EKG pattern and myocardial effects in a chronic propofol abuser. <i>Clin Toxicol (Phila)</i>. 2009;47(4):358-363. doi:10.1080/15563650902887842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19514884/pubmed" id="19514884" target="_blank">19514884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.1">
<a name="Roberts.1"></a>Roberts J. <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19874582">
<a name="19874582"></a>Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. <i>Crit Care</i>. 2009;13(5):R169. doi:10.1186/cc8145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19874582/pubmed" id="19874582" target="_blank">19874582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9009941">
<a name="9009941"></a>Robinson BJ, Ebert TJ, O'Brien TJ, Colinco MD, Muzi M. Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation? <i>Anesthesiology</i>. 1997;86(1):64-72. doi:10.1097/00000542-199701000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/9009941/pubmed" id="9009941" target="_blank">9009941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosero.1">
<a name="Rosero.1"></a>Rosero. Monitored anesthesia care in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 21, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8322572">
<a name="8322572"></a>Saarnivaara L, Hiller A, Oikkonen M. QT interval, heart rate and arterial pressures using propofol, thiopentone or methohexitone for induction of anaesthesia in children. <i>Acta Anaesthesiol Scand</i>. 1993;37(4):419-423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/8322572/pubmed" id="8322572" target="_blank">8322572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2343728">
<a name="2343728"></a>Saarnivaara L, Klemola UM, Lindgren L, Rautiainen P, Suvanto A. QT interval of the ECG, heart rate and arterial pressure using propofol, methohexital or midazolam for induction of anaesthesia. <i>Acta Anaesthesiol Scand</i>. 1990;34(4):276-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/2343728/pubmed" id="2343728" target="_blank">2343728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12131130">
<a name="12131130"></a>Sakabe M, Fujiki A, Inoue H. Propofol induced marked prolongation of QT interval in a patient with acute myocardial infarction. <i>Anesthesiology</i>. 2002;97(1):265-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/12131130/pubmed" id="12131130" target="_blank">12131130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32950175">
<a name="32950175"></a>Samal S, Singhania N, Adl D, Afzal O, Singhania G. Chocolate milk in CRRT circuit: propofol induced hypertriglyceridemia. <i>Am J Med Sci</i>. 2021;361(1):135-136. doi:10.1016/j.amjms.2020.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32950175/pubmed" id="32950175" target="_blank">32950175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23873972">
<a name="23873972"></a>Savard M, Dupré N, Turgeon AF, Desbiens R, Langevin S, Brunet D. Propofol-related infusion syndrome heralding a mitochondrial disease: case report. <i>Neurology</i>. 2013;81(8):770-771. doi:10.1212/WNL.0b013e3182a1aa78<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/23873972/pubmed" id="23873972" target="_blank">23873972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schumann.1">
<a name="Schumann.1"></a>Schumann R. Anesthesia for the obese patient. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24399312">
<a name="24399312"></a>Shearin AE, Patanwala AE, Tang A, Erstad BL. Predictors of hypotension associated with propofol in trauma patients. <i>J Trauma Nurs</i>. 2014;21(1):4-8. doi:10.1097/JTN.0000000000000022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24399312/pubmed" id="24399312" target="_blank">24399312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23889264">
<a name="23889264"></a>Simons SH, van der Lee R, Reiss IK, van Weissenbruch MM. Clinical evaluation of propofol as sedative for endotracheal intubation in neonates. <i>Acta Paediatr</i>. 2013;102(11):e487-492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/23889264/pubmed" id="23889264" target="_blank">23889264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35119438">
<a name="35119438"></a>Smith HAB, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine (SCCM) clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. <i>Pediatr Crit Care Med</i>. 2022;23(2):e74-e110. doi:10.1097/PCC.0000000000002873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/35119438/pubmed" id="35119438" target="_blank">35119438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077340">
<a name="31077340"></a>Sommerfield DL, Lucas M, Schilling A, et al. Propofol use in children with allergies to egg, peanut, soybean or other legumes. <i>Anaesthesia</i>. 2019;74(10):1252-1259. doi:10.1111/anae.14693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/31077340/pubmed" id="31077340" target="_blank">31077340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76. doi:10.1177/1060028013510488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20167123">
<a name="20167123"></a>Stuttmann R, Schäfer C, Hilbert P, Meyer MR, Maurer HH. The breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesia. <i>BMC Anesthesiol</i>. 2010;10:1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/20167123/pubmed" id="20167123" target="_blank">20167123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19825064">
<a name="19825064"></a>Tam MK, Irwin MG, Tse ML, Lui YW, Law KI, Ng PW. Prolonged myoclonus after a single bolus dose of propofol [published correction appears in <i>Anaesthesia</i>. 2010;65(2):222]. <i>Anaesthesia</i>. 2009;64(11):1254-1257. doi:10.1111/j.1365-2044.2009.06035.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/19825064/pubmed" id="19825064" target="_blank">19825064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12463387">
<a name="12463387"></a>Tanskanen PE, Kyttä JV, Randell TT. QT interval and QT dispersion during the induction of anaesthesia in patients with subarachnoid haemorrhage: a comparison of thiopental and propofol. <i>Eur J Anaesthesiol</i>. 2002;19(10):749-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/12463387/pubmed" id="12463387" target="_blank">12463387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9215013">
<a name="9215013"></a>Tramèr MR, Moore RA, McQuay HJ. Propofol and bradycardia: causation, frequency and severity. <i>Br J Anaesth</i>. 1997;78(6):642-651. doi:10.1093/bja/78.6.642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/9215013/pubmed" id="9215013" target="_blank">9215013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration. <i>FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women</i>. US Food and Drug Administration Web site. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm</a>. Published December 14, 2016. Updated April 27, 2017. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vuillaume.1">
<a name="Vuillaume.1"></a>Vuillaume C, Geeraerts T, Rollin A, Fourcade O, Maury P. ST elevation, long QT, and ventricular arrhythmias related to propofol infusion syndrome without biological abnormalities in a child after head injury. <i>The Journal of Innovations in Cardiac Rhythm Management</i>. 2014;5:1508-1511. doi:10.19102/icrm.2014.050105</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32822230">
<a name="32822230"></a>Vossler DG, Bainbridge JL, Boggs JG, et al. Treatment of refractory convulsive status epilepticus: a comprehensive review by the American Epilepsy Society Treatments Committee. <i>Epilepsy Curr.</i> Published online August 21, 2020. doi:10.1177/1535759720928269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32822230/pubmed" id="32822230" target="_blank">32822230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25493132">
<a name="25493132"></a>Waheed MA, Oud L. Acute pulmonary edema associated with propofol: an unusual complication. <i>West J Emerg Med</i>. 2014;15(7):845-848. doi:10.5811/westjem.2014.7.22942<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/25493132/pubmed" id="25493132" target="_blank">25493132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20659617">
<a name="20659617"></a>Warpechowski P, dos Santos AT, Pereira PJ, de Lima GG. Effects of propofol on the cardiac conduction system. <i>Rev Bras Anestesiol</i>. 2010;60(4):438-444. doi:10.1016/S0034-7094(10)70054-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/20659617/pubmed" id="20659617" target="_blank">20659617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20642659">
<a name="20642659"></a>Welzing L, Kribs A, Eifinger F, Huenseler C, Oberthuer A, Roth B. Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. <i>Paediatr Anaesth</i>. 2010;20(7):605-611.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/20642659/pubmed" id="20642659" target="_blank">20642659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26089466">
<a name="26089466"></a>Wiskin AE, Smith J, Wan SK, Nally MW, Shah N. Propofol anaesthesia is safe in children with food allergy undergoing endoscopy. <i>Br J Anaesth</i>. 2015;115(1):145-146. doi:10.1093/bja/aev177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/26089466/pubmed" id="26089466" target="_blank">26089466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33985368">
<a name="33985368"></a>Witenko CJ, Littlefield AJ, Abedian S, An A, Barie PS, Berger K. The safety of continuous infusion propofol in mechanically ventilated adults with coronavirus disease 2019. <i>Ann Pharmacother</i>. Published online May 14, 2021. doi:10.1177/10600280211017315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/33985368/pubmed" id="33985368" target="_blank">33985368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32692244">
<a name="32692244"></a>Xu G, Qiao N, Pan Y, Simayi A, Chen N. The appropriate dose of propofol for anesthesia induction in morbidly obese patients. A<i>nn Palliat Med</i>. 2020;9(4):1921-1927. doi:10.21037/apm-20-1223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/32692244/pubmed" id="32692244" target="_blank">32692244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211170">
<a name="22211170"></a>You BC, Jang AS, Han JS, et al. A case of propofol-induced oropharyngeal angioedema and bronchospasm. <i>Allergy Asthma Immunol Res</i>. 2012;4(1):46-48. doi:10.4168/aair.2012.4.1.46<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/22211170/pubmed" id="22211170" target="_blank">22211170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36042988">
<a name="36042988"></a>Zaki HA, Shallik N, Shaban E, et al. An analytical comparison between ketamine alone and a combination of ketamine and propofol (ketofol) for procedural sedation and analgesia from an emergency perspective: a systematic review and meta-analysis. <i>Cureus</i>. 2022;14(7):e27318. doi:10.7759/cureus.27318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/36042988/pubmed" id="36042988" target="_blank">36042988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17381434">
<a name="17381434"></a>Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. <i>Epilepsia</i>. 2007;48(5):1002-1006. doi:10.1111/j.1528-1167.2007.01042.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/17381434/pubmed" id="17381434" target="_blank">17381434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9066334">
<a name="9066334"></a>Zhou W, Fontenot HJ, Liu S, Kennedy RH. Modulation of cardiac calcium channels by propofol. <i>Anesthesiology</i>. 1997;86(3):670-675. doi:10.1097/00000542-199703000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propofol-pediatric-drug-information/abstract-text/9066334/pubmed" id="9066334" target="_blank">9066334</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12741 Version 517.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
